Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025in

Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial performance for the first three months of 2025. Revenue from Direct MagnetOs product sales rose 79% in the first three months of 2025, to USD 28.4 million from USD 15.8 million in Q1 2024. Total group revenue reached USD 28.8 million, up by 82% from USD 15.8 million in Q1 2024, with monthly revenue surpassing USD 10 million for the first time. The Group achieved an EBITDA of USD 2.0 million. Adjusted EBITDA excluding the recurring and one-time share-based compensation, and the relevant social security charges totaled USD 3.3 million, representing an adjusted EBITDA margin of 11.6%. At USD 19.5 million, cash and cash equivalents remained robust and almost at the same level as at the end of the year (Q4 2024: USD 19.8 million), despite significant investments in inventories amounting to around USD 2.8 million to hedge against the tariffs.

Based on the recent announcement from the U.S. government regarding new tariff measures, Kuros is currently evaluating potential implications, including those affecting medical devices and key raw materials. While it is too early to quantify the impact, the company has been taking proactive and mitigating actions to ensure continuity of supply, including increasing inventory levels and diversifying production into the US.

Additionally, Kuros continues to strengthen its global footprint, with MagnetOs Granules now commercially cleared in Brazil and MagnetOs Granules and Putty cleared in Lebanon. These milestones mark important steps in the company’s international expansion, increasing access to its innovative bone graft technology in Latin America and the Middle East.

Two newly published independent retrospective studies further validate the real-world clinical performance of MagnetOs in high-risk patient populations:

• Sandhu et al. (Published: World Neurosurgery, 2025):¹
  In a single-center retrospective study of 55 patients (93 treated levels) undergoing lumbar interbody fusion, MagnetOs Putty demonstrated a fusion rate of 95.7% at one year – despite patients having an average of three comorbidities and a median of two levels fused. These findings reinforce the potential of MagnetOs in complex, comorbidity-laden cases. Read the study
• Davis et al. (Accepted: Orthopedic Reviews, 2025):²
  MagnetOs Easypack Putty was evaluated as a standalone graft in 20 patients (36 treated levels) undergoing transforaminal lumbar interbody fusion procedures. Despite 65% of patients being obese, 35% diabetic, and 30% with prior lumbar surgery, the study showed a fusion rate of 94.4% at one year. Read the study

These additions to the MagnetOs clinical evidence base complement Kuros’ ongoing Project Fusion initiative and further support surgeons in making confident, evidence-based decisions for their patients.

Chris Fair, Chief Executive Officer of Kuros Biosciences, said: “The Group delivered an impressive start to the year, achieving USD 28.8 million in revenue for Q1 2025. Our initial launch into the extremity market coupled with our growing spine partnership with Medtronic, paves the way forward for growth and opportunities. Notably, we reached a new milestone with monthly revenue exceeding USD 10.0 million for the first time and we exceeded our financial operational targets for the quarter. This global performance reflects the continued momentum in our business, and operationally we remain ahead of the curve in ensuring we are proactive to the current tariff environment.” Mr. Fair continued, “With new commercial clearances, expanding clinical evidence and strong momentum in sales, we are off to an exceptional start in 2025. We remain committed to empowering clinicians with innovative biologics that support evidence-based decisions.”